Teva Pharma Industries Ltd ADR
$ 34.19
-0.70%
05 Jun - close price
- Market Cap 39,811,756,000 USD
- Current Price $ 34.19
- High / Low $ 35.01 / 34.09
- Stock P/E 25.51
- Book Value 7.07
- EPS 1.34
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.22 %
- 52 Week High 37.35
- 52 Week Low 14.99
About
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Analyst Target Price
$41.27
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-01-28 | 2025-11-05 | 2025-07-30 | 2025-05-07 | 2025-01-29 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-01-31 | 2023-11-08 | 2023-08-02 |
| Reported EPS | 0.53 | 0.41 | 0.78 | 0.66 | 0.52 | 0.71 | -0.39 | 0.61 | 0.48 | 1 | 0.6 | 0.56 |
| Estimated EPS | 0.46 | 0.2 | 0.67 | 0.62 | 0.46 | 0.7 | 0.66 | 0.55 | 0.51 | 0.76 | 0.61 | 0.53 |
| Surprise | 0.07 | 0.21 | 0.11 | 0.04 | 0.06 | 0.01 | -1.05 | 0.06 | -0.03 | 0.24 | -0.01 | 0.03 |
| Surprise Percentage | 15.2174% | 105% | 16.4179% | 6.4516% | 13.0435% | 1.4286% | -159.0909% | 10.9091% | -5.8824% | 31.5789% | -1.6393% | 5.6604% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.51 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.085 | $0.07225 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 | $0.289 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TEVA
2026-06-06 05:41:13
Wall Street Zen has upgraded Teva Pharmaceutical Industries (NYSE:TEVA) to a "buy" rating from "hold," contributing to a positive analyst sentiment. Several other analysts, including JPMorgan, Truist, Bank of America, and Piper Sandler, have also recently issued positive ratings or raised price targets for the stock. This comes after Teva reported strong quarterly results and positive business updates regarding AUSTEDO data and European biosimilar expansion.
2026-06-05 19:41:13
A director of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has filed a Form 144, notifying a proposed resale of 13,043 ordinary shares stemming from a restricted share unit award scheduled to vest on June 5, 2026. The filing also disclosed a past sale of 20,025 ordinary shares by Richard Francis on March 5, 2026, for $634,159.71. The notice is neutral, focusing on regulatory compliance for future and past share disposals.
2026-06-05 18:41:13
Teva Pharmaceutical Industries has launched AHZANTIVE, a biosimilar to Eylea, in Europe, expanding its presence in ophthalmology and adding to its biosimilars portfolio. This launch aligns with Teva's "Pivot to Growth" strategy focusing on complex biologic medicines. Despite recent stock fluctuations, Teva has seen significant multi-year gains, and analysts currently view the stock as undervalued.
2026-06-05 17:39:49
Alvotech (ALVO) stock surged 19% after the company resubmitted biologics license applications (BLAs) to the FDA for two biosimilar candidates, AVT05 and AVT06, which are proposed biosimilars to Simponi/Simponi Aria and Eylea, respectively. The resubmissions follow corrective measures taken after manufacturing deficiencies were identified in 2025 and an FDA inspection in May 2026. Both biosimilars have already been approved in multiple international markets, and Alvotech anticipates an FDA review within six months.
2026-06-05 15:39:49
Teva Pharmaceuticals announced new real-world data at the Advanced Therapeutics in Movement & Related Disorders Congress regarding AUSTEDO and AUSTEDO XR for Huntington's disease chorea. The study found that treatment significantly improved patient- and caregiver-reported quality of life, reducing daily life interference caused by chorea. These findings underscore the importance of effective chorea management in preserving patients' independence and alleviating caregiver burden.
2026-06-05 10:39:49
Straight Path Wealth Management significantly reduced its stake in Teva Pharmaceutical Industries Ltd. by selling 30,000 shares, decreasing its holdings by 37.5%. Despite this, institutional ownership of Teva remains strong at 54.05%, with several other funds increasing their positions. Analyst sentiment for Teva is largely positive, with a "Moderate Buy" consensus and an average target price of $41.78, following several price target increases from financial firms.
